• EFG Hermes advised on DPI’s USD 190M minority investment in Alameda Healthcare, marking a major private equity deal in Egypt.
• The capital increase will inject foreign currency into Egypt’s economy and support Alameda’s expansion across Egypt and the GCC.
• Alameda plans to scale hospital operations and clinical capacity, targeting growth in Egypt, Saudi Arabia, the UAE, and beyond.
  

EFG Hermes

EFG Hermes, an EFG Holding company and MENA investment bank, announced that its investment banking division acted as the sole M&A Financial Advisor on the signing of a USD 190 million minority stake investment in Alameda Healthcare by Development Partners International (DPI).

Established in 1999, Alameda Healthcare is an Egyptian private healthcare group aiming to offer patients personalized medical services across an expanding network of internationally respected hospitals. 

Maged El Ayouti, Co-Head of Investment Banking at EFG Hermes, said: “We are honored to have led this landmark transaction as the Sole M&A Financial Advisor, attracting $190 million for a significant minority stake in one of the leading and fast-growing healthcare platforms in the region.”

Alameda

The foreign direct investment is currently in its final stages and is expected to close in Q3 2025.   Following the transaction, Dr. Fahad Khater, Chairman of Alameda, will remain the group’s majority shareholder. Additionally, the transaction is primarily a capital increase and is subject to customary regulatory approvals. Thus, it will result  in foreign currency proceeds entering Egypt’s local banking system and support the company’s growth in Egypt and GCC markets. Furthermore, the investment reinforces investor confidence in backing resilient and fast-growing business across Egypt. 
The investment aims to consolidate Alameda’s position as a national healthcare leader. It also aims to enable its expansion across Egypt and the wider region. Furthermore, with the new capital Alameda aims to deliver and invest in expanding its  hospital operations and clinical capacity. In this, it aims to target Egypt and key markets in the region such as KSA, UAE, and other GCC markets.